Hybridon receives patent for Protein Kinase A oligonucleotide.Hybridon, Inc. (Cambridge, MA) announced the issuance of United States Patent 6,624,293 entitled, "Modified Protein Kinase protein kinase /pro·tein ki·nase/ (pro´ten ki´nas) an enzyme that catalyzes the phosphorylation of serine, threonine, or tyrosine groups in enzymes or other proteins, using ATP as a phosphate donor. A-Specific Oligonucleotides and Methods of Their Use," claiming 2nd generation antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). oligonucleotides targeting the RI alpha regulatory subunit of Protein Kinase A. Included in the patent are product claims covering Hybridon's GEM231 2nd generation antisense drug candidate. Other issued claims in the patent cover several other modified versions of the GEM231 product and therapeutic compositions containing 2nd generation oligonucleotides.The present patent along with the parent, United States Patent 5,969,117, give Hybridon a broad portfolio of 2nd generation antisense oligonucleotides targeting the RI alpha subunit alpha subunit first-named chain (or subunit) occurring in the functional organization of macromolecules, usually proteins, containing two or more chains. of PKA pK a /pK a/ the negative logarithm of the ionization constant (K) of an acid, the pH of a solution in which half of the acid molecules are ionized. . In addition, the present patent further expands the patent protection of Hybridon's 2nd generation antisense chemistry employed in GEM231 and covered by previously issued patents including United States Patent Nos. 5,652,355; 6,143,881; 6,346,614 and their oral delivery United States Patent Nos. 5,591,721; 6,608,035. Presently, Hybridon is conducting a phase 1/2 trial at Vanderbilt University Medical Center The Vanderbilt University Medical Center (VUMC) is a collection of several hospitals and clinics associated with Vanderbilt University in Nashville, Tennessee. It comprises the following units:[2]
Sole inventor on the 6,624,293 patent is Dr. Sudhir Agrawal, Hybridon's President and Chief Scientific Officer. Dr. Agrawal is also a co-inventor of the other patents listed in this release. Hybridon is a leader in the discovery and development of novel therapeutics and diagnostics, based on synthetic DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. . The Company now has four technology platforms: 1) Synthetic immunomodulatory oligonucleotide (IMOTM) motifs that act to modulate responses of the immune system; 2) Antisense technology which uses synthetic DNA to block the production of disease-causing proteins at the cellular level; 3) Synthetic DNA drug candidates that enhance the antitumor an·ti·tu·mor also an·ti·tu·mor·al adj. Counteracting or preventing the formation of malignant tumors; anticancer. Adj. 1. activity of certain marketed anticancer drugs, thereby increasing their effectiveness; and 4) Cyclicon probes, novel synthetic DNA structures for identifying gene function, which can be used for target validation and drug discovery as well as for PCR-based gene amplification. Hybridon, Inc. +1-617-679-5500 www.hybridon.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion